Increase of human prostate cancer cell (DU145) apoptosis by telmisartan through PPAR-delta pathway
Authors:
- 1 March 2016
- journal article
- Published by Elsevier in European Journal of Pharmacology
- Vol. 775, 35-42
Abstract
No abstract availableKeywords
Funding Information
- National Science Council (102-2314-B-006-071)
- Ministry of Science and Technology (103-2314-B-006-074-MY2)
This publication has 28 references indexed in Scilit:
- Telmisartan enhances mitochondrial activity and alters cellular functions in human coronary artery endothelial cells via AMP-activated protein kinase pathwayAtherosclerosis, 2015
- Down-modulation of Bcl-2 sensitizes PTEN-mutated prostate cancer cells to starvation and taxanesThe Prostate, 2014
- Telmisartan Induces Growth Inhibition, DNA Double-Strand Breaks and Apoptosis in Human Endometrial Cancer CellsPLOS ONE, 2014
- Telmisartan complex augments solubility, dissolution and drug delivery in prostate cancer cellsCarbohydrate Polymers, 2014
- Troglitazone, a PPAR agonist, inhibits human prostate cancer cell growth through inactivation of NFκB via suppression of GSK-3β expressionCancer Biology & Therapy, 2011
- Angiotensin II receptor blocker telmisartan enhances running endurance of skeletal muscle through activation of the PPAR-δ/AMPK pathwayJournal of Cellular and Molecular Medicine, 2010
- Telmisartan Prevents Weight Gain and Obesity Through Activation of Peroxisome Proliferator-Activated Receptor-δ–Dependent PathwaysHypertension, 2010
- Delivery of siRNA from lyophilized polymeric surfacesBiomaterials, 2008
- Identification of Telmisartan as a Unique Angiotensin II Receptor Antagonist With Selective PPARγ–Modulating ActivityHypertension, 2004
- The Mechanisms of Action of PPARsAnnual Review of Medicine, 2002